It seems SuperGen Inc. decided to change its course. Just weeks after disclosing plans to withdraw a proposed stock offering, the cancer drug development company raised $34 million through a stock-and-warrant sale. (BioWorld Today)
It seems SuperGen Inc. decided to change its course. Just weeks after disclosing plans to withdraw a proposed stock offering, the cancer drug development company raised $34 million through a stock-and-warrant sale. (BioWorld Today)
Reporting for the first time as a combined entity, Biogen Idec Inc. missed consensus earnings estimates by 8 cents, posting pro forma earnings per share of 24 cents for the fourth quarter. Its full-year adjusted EPS totaled $1.22. (BioWorld Today)
Reporting for the first time as a combined entity, Biogen Idec Inc. missed consensus earnings estimates by 8 cents, posting pro forma earnings per share of 24 cents for the fourth quarter. Its full-year adjusted EPS totaled $1.22. (BioWorld Today)
